Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...
1don MSN
Eli Lilly ( LLY 2.31%) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive ...
U.S. Secretary of Commerce Howard Lutnick said Lilly was doing "exactly what the President was hoping would happen." ...
Eli Lilly stock surges past $840, outperforming the S&P 500. Click here to learn why LLY stock is still undervalued and why ...
Eli LIlly & Co. said Tuesday it is launching 7.5 and 10 milligram versions of its Zepbound single-dose vials at a price of $499-a-month for self-pay patients, down from $699 previously.
Eli Lilly kicks off 2025 with key licensing deals and M&A, boosting its position across therapeutic areas amid rising drug ...
Citi analyst Geoff Meacham reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $1,190.00. The ...
Eli Lilly wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results